Who
Jay S. Skyler
Director
Company insider
Files Form 4 as: Director, Applied Therapeutics; Director, SAB Biotherapeutics; Director, DexCom; Director, Amylin Pharmaceuticals.
In numbers
- Trades disclosed
- 178
- Buys
- 3
- Sells
- 20
- Bought
- $1.2M
- Sold
- $41.3M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 4 Oct 2005
- Last trade
- 3 Feb 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code U | —42,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code D | —22,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code U | —42,500 | filing |
| 16 Dec 2025filed 18 Dec 2025 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | Applied Therapeutics | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | Applied Therapeutics | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Vontobel Holding Ltd. Sells 14,970 Shares of DexCom, Inc. $DXCMDXCM · dailypolitical.com · 20 Oct 2026DexCom, Inc. $DXCM Position Lowered by Gradient Investments LLCDXCM · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Jay S. Skyler; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.